Navigation Links
Lialda in Medical News

Long-term safety data on Lialda published in leading GI journal

Basingstoke, UK and Philadelphia, US June 17, 2008 Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™...

New Analyses of long-term LIALDA (mesalamine) data presented at ACG

Philadelphia, PA October 15, 2007 Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate u...

Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans

...nts who are newly prescribed or are already taking lialda or Pentasa and who become unemployed in 2009 can r...ar. In addition, more UC patients can benefit from lialda and Pentasa because Shire has raised the household...am (not valid in Mass.) and a 30-day free trial of lialda when patients join the...

Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease

...rapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyor...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...tudy were to assess the safety and tolerability of lialda in mild-to-moderate UC patients over 12 months. Da...terology. "This published data demonstrates that lialda is generally well tolerated and has a strong safet... the 303 study show that a majority of patients on lialda continued to remain in remission through 12 months...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...ith UC will develop colon cancer. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Nationwide survey reveals differing physician and patient perceptions regarding impact of UC

...tions on Remission Management and Lifestyle), were sponsored by Shire Pharmaceuticals, a specialty biopharmaceutical company, which markets once-daily lialda and PENTASA (mesalamines) for UC. Before these surveys, patient and physician views on UCs impact had not been compared and the real-life impact o...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...ssen the burden," said Dr. Rubin. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

... 43.7 18% 2% 17% lialda 16.3 n/a n/a ...price increases in November 2006 and August 2007. lialda - Ulcerative colitis Shire launched lialda during March 2007. By September 30, 2007 LIALDA ha...

LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

..., NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug lialda (mesalamine) demonstrated a delivery system where ...erative colitis. In this in vitro model, after the lialda tablet passed through the simulated stomach, small...n adult GI tract, we were able to demonstrate that lialda tablets provide maximum release of 5-ASA in a prol...
Lialda in Medical Technology

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... of therapy for continuing patients, 20 percent of lialda patients were continually persistent, 9 percent of...tion of the prescription that preceded the refill. lialda is an FDA-approved, once-daily oral medication for...cerative colitis (UC). Safety and effectiveness of lialda beyond eight weeks have not been established. ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...om St Mark's Hospital in London, UK), demonstrated lialda was effective in inducing remission in patients wi... 8-week study. Patients in the Kamm study received lialda 2.4g/day once daily (n=84), 4.8g/day once daily (n... the definition used for remission, treatment with lialda 2.4g/day, or 4.8g/day, or Asacol 2.4g/day resulted...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...ug LIALDA(TM) (mesalamine) provide further data on lialda in patients with mild to moderate ulcerative colit...3 was safety and tolerability and findings -- that lialda is generally well tolerated in mild to moderate UC...tland in March 2007. "Earlier studies showed that lialda is well-tolerated and effective at inducing remiss...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

... people with UC will develop colon cancer. About lialda lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...
Lialda in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 4.9 n/a n/a n/a(5) n/a(5) lialda / MEZAVANT 54.6 71% 73% ... 54.0 44.8 21% 8% lialda / MEZAVANT 54.6 32.0 7... 105.2 89.0 18% 7% lialda / MEZAVANT 104.0 59.2 76...

Shire begins the year with a strong performance

...ncome within revenues. License agreement for lialda in Japan - On January 16, 2009 Shire announce...LDA(R) (mesalamine) in Japan. Termination of lialda co-promotion agreement - As of March 31, 2009...tical Products Inc., for the co-promotion of lialda in the US. Pipeline DAYTRANA - for the t...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... Pharmaceutical Co., Ltd to develop and sell lialda in Japan. - On February 9, 2009 Shire announc... 78.7 +23% -11% 1.8% lialda / MEZAVANT 140.4 +178% +204% ...er 31, 2008 (2007: 21.1%), driven by the growth of lialda since its launch in March 2007. LIALDA/MEZA...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... first time. The performance of ELAPRASE, VYVANSE, lialda and FOSRENOL ROW were particularly strong. This qu... 18.1 93% -14% 1.6% lialda / MEZAVANT 40.4 148% +143% ...er 30, 2008 (2007: 22.5%), driven by the growth of lialda since its launch in March 2007. The overall US ora...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...oduct sales comprise DAYTRANA, ELAPRASE, FOSRENOL, lialda / MEZAVANT and VYVANSE Angus Russell, Chief...Products Inc. ("TAP") commenced co-promotion of lialda in the US in accordance with the co-promotion a... 22.6 14% -11% 1.8% lialda / MEZAVANT 32.0 n/a n/a ...

Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards

...mpaigns." Cadient Group received the following Communicator Awards: -- lialda - Silver Communicator Award Cadient Group was recognized for its work with Shire US, Inc.'s lialda Web site, which offers information, tools, and resources for people ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...uency of our sales calls. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...VANT(R) - Ulcerative Colitis - By April 11, 2008 lialda had achieved a 9.8% share of the US oral mesalamin...hire's share of the US oral mesalamine market from lialda and PENTASA combined increased to 26.1% for the th...

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

...of 120 representatives who are currently detailing lialda primarily to gastroenterologists. "Aligning with...mendous benefit for Shire as it will quadruple the lialda sales force across the United States," said Mike Y...th messages about Lialda. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...

Shire plc: IFRS Results for the Year Ending December 31, 2007

...LDA/MEZAVANT - Ulcerative colitis Shire launched lialda in the US oral mesalamine market in March 2007, and by December 31, 2007 lialda had reached a market share of 8.0% (average annual...were US$50.5 million. All initial launch stocks of lialda totaling US$34.3 million were recognised into reve...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

...ertook three major new product launches - VYVANSE, lialda / MEZAVANT and DYNEPO - which have gone well and a...hire's share of the US oral mesalamine market from lialda and PENTASA(R) combined was 26.0% at February 8, 2... 176.4 +28% +3% 17.2% lialda 50.5 n/a n/a ...
Other Tags
(Date:9/1/2015)... UK (PRWEB) , ... September ... ... constantly seeking better therapeutic options to efficiently cure and prevent different malignancies. ... Different cancers have different pathophysiological properties due to which distinctive approach is ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure ... inside a wound to remove exudates, fluid, and infectious materials to prepare the ... stand-alone devices, disposable devices, and canisters, etc.) is projected to expand continuously through ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Screeners (NAPBS®) has announced that Edge Information Management has been granted ... Background Screening Credentialing Council (BSCC). , ÔÇťAchieving and maintaining this accreditation ...
(Date:9/1/2015)... Francisco, Calif. (PRWEB) , ... September 01, 2015 ... ... to corporations, law firms and government entities, announced today that it has hired ... Senior Discovery Consultant. In this capacity, Sanderson will be responsible for establishing ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
Other Contents